

First geneType™ Clinical Test Sale in S. E Asia

Highlights

- ✓ Rhythm completes the first commercial sale of its geneType™ cancer risk assessment clinical test in the Philippines, the first sale in South East Asia.
- ✓ This transaction begins a process of scaling up of sales in the region ahead of expansion into other South East Asian geographies.

Melbourne, Australia, 26th March 2026: Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX: RHY), a transformative, predictive cancer diagnostics technology company is pleased to report the first sale of a geneType™ cancer risk assessment test in Manila, Philippines.

Rhythm announced the partnership in the region with Digistain on 4th March 2026 and is pleased to see the first sale within weeks of the commencement of the commercialisation process. Southeast Asia represents a market with a large population base, increasing healthcare expenditure, improving access to private healthcare, and relatively low current penetration of advanced cancer risk assessment tests such as geneType™.

The first patient was motivated to use geneType™ to understand their cancer risk beyond traditional hereditary testing frameworks, given that the majority of cancers arise in individuals without a qualifying family history.

The successful completion of this first commercial clinical test confirms that the Digistain team have effectively completed the initial commercial pilot and will now scale sales across the Philippines ahead of setting up pilots in other S. E Asian geographies. While initial test volumes are expected to be modest, the Company anticipates increasing sales as clinician adoption and distribution channels develop across the region.

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

Directors

Gavin Fox-Smith
Sue MacLeman
David Atkins

Non-Executive Chairman
Non-Executive Director
CEO & Managing Director

www.rhythmbio.com

T +61 3 8256 2880
E info@rhythmbio.com

Dr Hemmel Amrania, CEO of Digistain Limited, commented: “We are pleased to see this first geneType™ sale and are optimistic about the impact we can have on cancer risk management in the region.”

The Company will provide updates on commercial progress and adoption rates through its regular quarterly reporting.

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Bioscience’s simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT® Test is based on research from Australia’s CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.

For personal use only